Medtronic PLC Net Worth
Medtronic PLC Net Worth Breakdown | MDT |
Medtronic PLC Net Worth Analysis
Medtronic PLC's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Medtronic PLC's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Medtronic PLC's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Medtronic PLC's net worth analysis. One common approach is to calculate Medtronic PLC's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Medtronic PLC's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Medtronic PLC's net worth. This approach calculates the present value of Medtronic PLC's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Medtronic PLC's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Medtronic PLC's net worth. This involves comparing Medtronic PLC's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Medtronic PLC's net worth relative to its peers.
Enterprise Value |
|
To determine if Medtronic PLC is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Medtronic PLC's net worth research are outlined below:
| Medtronic PLC generated a negative expected return over the last 90 days | |
| Over 85.0% of the company shares are owned by institutional investors | |
| On 11th of October 2024 Medtronic PLC paid $ 0.7 per share dividend to its current shareholders | |
| Latest headline from investing.com: Disposition of 1540 shares by Gary Corona of Medtronic PLC at 80.0 subject to Rule 16b-3 |
Medtronic PLC Quarterly Good Will |
|
Medtronic PLC uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Medtronic PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Medtronic PLC's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 23rd of May 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 23rd of May 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Know Medtronic PLC's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Medtronic PLC is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Medtronic PLC backward and forwards among themselves. Medtronic PLC's institutional investor refers to the entity that pools money to purchase Medtronic PLC's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2024-06-30 | 16.7 M | Franklin Resources Inc | 2024-09-30 | 16.6 M | Norges Bank | 2024-06-30 | 15.6 M | Legal & General Group Plc | 2024-06-30 | 11.6 M | Royal Bank Of Canada | 2024-06-30 | 11.4 M | Northern Trust Corp | 2024-09-30 | 11.4 M | Ameriprise Financial Inc | 2024-06-30 | 10.9 M | Amvescap Plc. | 2024-06-30 | 10.8 M | Alliancebernstein L.p. | 2024-06-30 | 10.7 M | Vanguard Group Inc | 2024-09-30 | 123.4 M | Blackrock Inc | 2024-06-30 | 111.9 M |
Follow Medtronic PLC's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 109.89 B.Market Cap |
|
Project Medtronic PLC's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.10 | 0.11 | |
| Return On Capital Employed | 0.06 | 0.05 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.07 | 0.07 |
When accessing Medtronic PLC's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Medtronic PLC's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Medtronic PLC's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Medtronic PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medtronic PLC. Check Medtronic PLC's Beneish M Score to see the likelihood of Medtronic PLC's management manipulating its earnings.
Evaluate Medtronic PLC's management efficiency
Medtronic PLC has Return on Asset of 0.0442 % which means that on every $100 spent on assets, it made $0.0442 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0795 %, implying that it generated $0.0795 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.11 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. Total Current Liabilities is likely to gain to about 11.3 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 94.5 B in 2024| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 37.98 | 38.37 | |
| Tangible Book Value Per Share | (2.86) | (6.02) | |
| Enterprise Value Over EBITDA | 15.93 | 24.28 | |
| Price Book Value Ratio | 2.11 | 3.42 | |
| Enterprise Value Multiple | 15.93 | 24.28 | |
| Price Fair Value | 2.11 | 3.42 | |
| Enterprise Value | 179 B | 187.9 B |
Management at Medtronic PLC focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 3.9494 | Revenue 32.6 B | Quarterly Revenue Growth 0.028 | Revenue Per Share 24.709 | Return On Equity 0.0795 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Medtronic PLC insiders, such as employees or executives, is commonly permitted as long as it does not rely on Medtronic PLC's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Medtronic PLC insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Medtronic PLC Corporate Filings
10Q | 26th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 19th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 24th of October 2024 Other Reports | ViewVerify | |
| 5th of September 2024 Other Reports | ViewVerify |
Medtronic PLC Earnings per Share Projection vs Actual
Medtronic PLC Corporate Directors
| Scott Donnelly | Lead Independent Director | Profile | |
| Richard Anderson | Lead Independent Director | Profile | |
| Elizabeth Nabel | Independent Director | Profile | |
| James Lenehan | Independent Director | Profile |
Additional Tools for Medtronic Stock Analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.